Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antibacterials - Pylum Biosciences

Drug Profile

Research programme: antibacterials - Pylum Biosciences

Alternative Names: Acinetobacter infection therapy - Pylum Biosciences; Avidocin therapeutics; Avidocin™ proteins; Clostridium difficile infection therapy - Pylum Biosciences; Escherichia coli infection therapy - Pylum Biosciences; Pseudomonas aeruginosa infection therapy - Pylum Biosciences; Yersinia pestis therapy - Pylum Biosciences

Latest Information Update: 29 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AvidBiotics Corp.
  • Class Bacteriocins; Proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Clostridium infections
  • Research Acinetobacter infections; Escherichia coli infections; Prevotella infections; Pseudomonal infections
  • No development reported Shiga-toxigenic Escherichia coli infections; Yersinia infections

Most Recent Events

  • 29 Jan 2018 Early research in Prevotella infections in USA (unspecified route) (AvidBiotics pipeline, January 2018)
  • 07 Nov 2017 Antibacterials are still in early research in Acinetobacter-infections, Escherichia coli infections, Gram-negative infections and Pseudomonal infections in USA (AvidBiotics Pipeline, November 2017)
  • 07 Nov 2017 Antibacterials are still in preclinical development for Clostridium difficile infections in USA (Avidbiotics pipeline, November 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top